Valuation: Galapagos NV

Market Cap 1.74B 1.99B 1.6B 1.49B 2.82B 189B 2.87B 19.22B 7.48B 93.12B 7.46B 7.3B 322B P/E 2026 *
-9.08x
P/E 2027 * -10.5x
Enterprise Value -915M -1.05B -843M -781M -1.48B -99.21B -1.51B -10.11B -3.93B -48.96B -3.92B -3.84B -169B EV / Sales 2026 *
-6.08x
EV / Sales 2027 * -5.34x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 13/05/2025
Director of Finance/CFO 43 07/07/2025
Chief Tech/Sci/R&D Officer 61 08/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 13/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.99B
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.84%+2.30%+422.47%+625.99% 40.39B
+1.26%+7.79%+28.21%-3.93% 34.38B
-0.60%+7.87%+27.55%+62.17% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+1.04%+1.57% - - 16.64B
-3.02%+3.52%+71.92%+132.77% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.55%+8.45%+105.82%+105.82% 13.75B
Average +0.41%+3.64%+84.79%+123.45% 27.33B
Weighted average by Cap. +0.34%+4.10%+96.26%+141.91%

Financials

2026 *2027 *
Net sales 150M 172M 139M 129M 244M 16.32B 248M 1.66B 647M 8.05B 646M 632M 27.84B 132M 151M 122M 113M 214M 14.33B 218M 1.46B 568M 7.07B 567M 555M 24.44B
Net income -261M -298M -240M -223M -423M -28.28B -430M -2.88B -1.12B -13.96B -1.12B -1.09B -48.24B -145M -166M -134M -124M -235M -15.74B -239M -1.6B -624M -7.77B -623M -609M -26.86B
Net Debt -2.65B -3.03B -2.45B -2.27B -4.3B -288B -4.37B -29.33B -11.41B -142B -11.39B -11.14B -491B -2.44B -2.79B -2.25B -2.09B -3.96B -265B -4.03B -27.02B -10.51B -131B -10.49B -10.26B -452B
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
B